The latest announcement is out from Elite Pharmaceuticals ( (ELTP) ).
Elite Pharmaceuticals, Inc. has announced the commercial launch of its generic version of Tylenol® with Codeine in various dosages, marking a significant step in the company’s niche generic product offerings. The medication is intended for the management of mild to moderate pain where an opioid is appropriate, and alternatives are inadequate, boasting sales of approximately $47 million in the past year. With its facilities in Northvale, NJ, Elite Pharmaceuticals continues to develop and manufacture controlled-release oral dose products, contributing to the competitive pharmaceutical market.
See more data about ELTP stock on TipRanks’ Stock Analysis page.
